A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-12 and is reviewed periodically as new material appears.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Peter Giles later called it one of Fripp's "cute political moves". According to Michael Giles, his brother had become disillusioned with the band's lack of success and departed before Fripp ever made this suggestion.
In 2006, a toxic waste spill off the coast of Côte d'Ivoire, from a European ship, prompted the commission to look into legislation against toxic waste. Environment Commissioner Stavros Dimas stated that "Such highly toxic waste should never have left the European Union". With countries such as Spain not even having a crime against shipping toxic waste, Franco Frattini, the Justice, Freedom and Security Commissioner, proposed with Dimas to create criminal sentences for "ecological crimes". The competence for the Union to do this was contested in 2005 at the Court of Justice resulting in a victory for the commission. That ruling set a precedent that the commission, on a supranational basis, may legislate in criminal law – something never done before. So far, the only other proposal has been the draft intellectual property rights directive. Motions were tabled in the European Parliament against that legislation on the basis that criminal law should not be an EU competence, but was rejected at vote. However, in October 2007, the Court of Justice ruled that the commission could not propose what the criminal sanctions could be, only that there must be some.
=== Advanced platelet-rich fibrin === Blood-derived growth factors have been used in medicine and oral surgery for more than twenty years with an abundance of scientific data supporting its role in soft and hard tissue regeneration. APRF, introduced by Dr. Joseph Choukroun, represents the fourth improved generation of such technology and has been widely used in the field of dentistry and oral surgery. Advantages of APRF include no risk of rejection or disease transmission (using your own blood) and improved healing (autogenous growth factors, hematopoietic or mesenchymal stem cells).
Sources: en.wikipedia.org
Rinck PA (ed.). "MRI: A Peer-Reviewed, Critical Introduction". European Magnetic Resonance Forum (EMRF)/The Round Table Foundation (TRTF). A Guided Tour of MRI: An introduction for laypeople National High Magnetic Field Laboratory The Basics of MRI. Underlying physics and technical aspects. Video: What to Expect During Your MRI Exam from the Institute for Magnetic Resonance Safety, Education, and Research (IMRSER) Royal Institution Lecture – MRI: A Window on the Human Body A Short History of Magnetic Resonance Imaging from a European Point of View How MRI works explained simply using diagrams Real-time MRI videos: Biomedizinische NMR Forschungs GmbH. Paul C. Lauterbur, Genesis of the MRI (Magnetic Resonance Imaging) notebook, September 1971 (all pages freely available for download in variety of formats from Science History Institute Digital Collections at digital.sciencehistory.org) Images showing early MRI scans and the development of the MRI scanner from the archives of University of Nottingham Manuscripts and Spcial Collections Archive collections relating to the development of MRI at the University of Nottingham, including the papers of Nobel Prize winner Sir Peter Mansfield
=== United Kingdom === Rhodesia was originally a self-governing British crown colony. Although decolonisation in Africa had begun after World War II, it began accelerating in the early 1960s, causing Britain to negotiate independence rapidly with several of its colonies. During this period, it adopted a foreign policy called NIBMAR, or No Independence Before Majority African Rule, mandating democratic reforms that placed governance in the hands of the majority black Africans. The governing white minority of Rhodesia, led by Ian Smith, opposed the policy and its implications. On 11 November 1965, Rhodesia's minority white government made a unilateral declaration of independence (UDI) from the United Kingdom, as it became apparent that negotiations would not lead to independence under the white regime. The United Kingdom government immediately brought in legislation (Southern Rhodesia Act 1965) which formally abolished all Rhodesian government institutions. This move made life difficult for Rhodesian citizens who wished to travel internationally as passports issued by Rhodesia's UDI administration were not recognised as valid; in January 1966, the British issued a statement accepting as valid any passport issued before the declaration of independence and allowing six-month United Kingdom passports to be granted when they expired – provided that the bearer declared they did not intend to aid the UDI Rhodesian government.
==== MeSH D12.776.377.715.182 – beta-globulins ==== MeSH D12.776.377.715.182.100 – beta-2 microglobulin MeSH D12.776.377.715.182.160 – beta-thromboglobulin MeSH D12.776.377.715.182.200 – complement factor h MeSH D12.776.377.715.182.338 – hemopexin MeSH D12.776.377.715.182.580 – plasminogen MeSH D12.776.377.715.182.580.500 – angiostatins MeSH D12.776.377.715.182.624 – properdin MeSH D12.776.377.715.182.800 – sex hormone-binding globulin MeSH D12.776.377.715.182.839 – transferrin
=== Central nervous system stimulants === Some systematic reviews and meta-analyses of clinical research using low doses of certain central nervous system stimulants have indicated that these drugs may enhance cognition in healthy people. In particular, the classes of stimulants that demonstrate possible cognition-enhancing effects in humans have evidence in vitro as direct agonists or indirect agonists of dopamine receptor D1 or adrenoceptor α2. Relatively high doses of stimulants cause cognitive deficits.
Sources: en.wikipedia.org
Science and religion are two windows that people look through, trying to understand the big universe outside, trying to understand why we are here. The two windows give different views, but they look out at the same universe. Both views are one-sided, and neither is complete. Both leave out essential features of the real world. And both are worthy of respect. Trouble arises when either science or religion claims universal jurisdiction when either religious or scientific dogma claims to be infallible. Religious creationists and scientific materialists are equally dogmatic and insensitive. By their arrogance, they bring both science and religion into disrepute. The media exaggerate their numbers and importance. The media rarely mention the fact that the great majority of religious people belong to moderate denominations that treat science with respect or the fact that the great majority of scientists treat religion with respect so long as religion does not claim jurisdiction over scientific questions. I do not claim any ability to read God's mind. I am sure of only one thing. When we look at the glory of stars and galaxies in the sky and the glory of forests and flowers in the living world around us, it is evident that God loves diversity. Perhaps the universe is constructed according to a principle of maximum diversity. The principle of maximum diversity says that the laws of nature, and the initial conditions at the beginning of time, are such as to make the universe as interesting as possible. As a result, life is possible but not too easy.
== Flow == The movement of fluid through a porous medium such as paper is governed by permeability (earth sciences), geometry and evaporation effects. Collectively these factors results in evaporation limited capillary penetration that can be tuned by controlling porosity and device geometry. Paper is a porous medium in which fluid is transported primarily by wicking and evaporation. The capillary flow during wetting can be approximated by Washburn's equation, which is derived from Jurin's law and the Hagen–Poiseuille equation. The average velocity of fluid flow is generalized as,
Das RC, Heath EC (1980). "Dolichyldiphosphoryloligosaccharide--protein oligosaccharyltransferase; solubilization, purification, and properties". Proc. Natl. Acad. Sci. U.S.A. 77 (7): 3811–5. Bibcode:1980PNAS...77.3811D. doi:10.1073/pnas.77.7.3811. PMC 349716. PMID 6933437.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.